Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies

Abstract

Temozolomide, an oral cytotoxic agent with approximately 100% bioavailability after one administration, has demonstrated schedule-dependent clinical activity against highly resistant cancers. Thirty patients with minimal prior chemotherapy were enrolled in this phase I trial to characterize the drug's safety, pharmacokinetics and anti-tumour activity, as well as to assess how food affects oral bioavailability. To determine dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD), temozolomide 100-250 mg m(-2) was administered once daily for 5 days every 28 days. The DLT was thrombocytopenia, and the MTD was 200 mg m(-2) day(-1). Subsequently, patients received the MTD to study how food affects the oral bioavailability of temozolomide. When given orally once daily for 5 days, temozolomide was well tolerated and produced a non-cumulative, transient myelosuppression. The most common non-haematological toxicities were mild to moderate nausea and vomiting. Clinical activity was observed against several advanced cancers, including malignant glioma and metastatic melanoma. Temozolomide demonstrated linear and reproducible pharmacokinetics and was rapidly absorbed (mean Tmax approximately 1 h) and eliminated (mean t1/2 = 1.8 h). Food produced a slight reduction (9%) in absorption of temozolomide. Temozolomide 200 mg m(-2) day(-1) for 5 days, every 28 days, is recommended for phase II studies.

References 18

1. 1.

   Bleehen N. M., Newlands E. S., Lee S. M., Thatcher N., Selby P., Calvert A. H., Rustin G. J., Brampton M., Stevens M. F. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol. 1995;13(4):910-913.

   Not in our library10.1200/jco.1995.13.4.910

2. 2.

   Bower M., Newlands E. S., Bleehen N. M., Brada M., Begent R. J., Calvert H., Colquhoun I., Lewis P., Brampton M. H. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol. 1997;40(6):484-488.

   Not in our library10.1007/s002800050691

3. 3.

   Catapano C. V., Broggini M., Erba E., Ponti M., Mariani L., Citti L., D'Incalci M. In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res. 1987;47(18):4884-4889.

   Not in our library

4. 4.

   D'Atri S., Piccioni D., Castellano A., Tuorto V., Franchi A., Lu K., Christiansen N., Frankel S., Rustum Y. M., Papa G. Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol. 1995;6(4):389-393.

   Not in our library10.1093/oxfordjournals.annonc.a059189

5. 5.

   Denny B. J., Wheelhouse R. T., Stevens M. F., Tsang L. L., Slack J. A. NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry. 1994;33(31):9045-9051.

   Not in our library10.1021/bi00197a003

6. 6.

   Dhodapkar M., Rubin J., Reid J. M., Burch P. A., Pitot H. C., Buckner J. C., Ames M. M., Suman V. J. Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res. 1997;3(7):1093-1100.

   Not in our library

7. 7.

   Friedman H. S., Dolan M. E., Pegg A. E., Marcelli S., Keir S., Catino J. J., Bigner D. D., Schold S. C. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res. 1995;55(13):2853-2857.

   Not in our library

8. 8.

   Kim H. K., Lin C. C., Parker D., Veals J., Lim J., Likhari P., Statkevich P., Marco A., Nomeir A. A. High-performance liquid chromatographic determination and stability of 5-(3-methyltriazen-1-yl)-imidazo-4-carboximide, the biologically active product of the antitumor agent temozolomide, in human plasma. J Chromatogr B Biomed Sci Appl. 1997;703(1-2):225-233.

   Not in our library10.1016/s0378-4347(97)00431-3

9. 9.
   Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856) · 1992

   No notice
10. 10.

    Newlands E. S., O'Reilly S. M., Glaser M. G., Bower M., Evans H., Brock C., Brampton M. H., Colquhoun I., Lewis P., Rice-Edwards J. M. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer. 1996;32A(13):2236-2241.

    Not in our library10.1016/s0959-8049(96)00258-4

11. 11.

    O'Reilly S. M., Newlands E. S., Glaser M. G., Brampton M., Rice-Edwards J. M., Illingworth R. D., Richards P. G., Kennard C., Colquhoun I. R., Lewis P. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer. 1993;29A(7):940-942.

    Not in our library10.1016/s0959-8049(05)80198-4

12. 12.

    Plowman J., Waud W. R., Koutsoukos A. D., Rubinstein L. V., Moore T. D., Grever M. R. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 1994;54(14):3793-3799.

    Not in our library

13. 13.

    Shen F., Decosterd L. A., Gander M., Leyvraz S., Biollax J., Lejeune F. Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr B Biomed Appl. 1995;667(2):291-300.

    Not in our library10.1016/0378-4347(95)00040-p

14. 14.

    Stevens M. F., Hickman J. A., Langdon S. P., Chubb D., Vickers L., Stone R., Baig G., Goddard C., Gibson N. W., Slack J. A. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987;47(22):5846-5852.

    Not in our library

15. 15.

    Tsang L. L., Farmer P. B., Gescher A., Slack J. A. Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicity. Cancer Chemother Pharmacol. 1990;26(6):429-436.

    Not in our library10.1007/bf02994094

16. 16.

    Wedge S. R., Porteous J. K., Glaser M. G., Marcus K., Newlands E. S. In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs. 1997;8(1):92-97.

    Not in our library10.1097/00001813-199701000-00013

17. 17.

    Wedge S. R., Porteous J. K., Newlands E. S. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer. 1996;74(7):1030-1036.

    Not in our library10.1038/bjc.1996.485

18. 18.

    Wedge S. R., Porteous J. K., Newlands E. S. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol. 1997;40(3):266-272.

    Not in our library10.1007/s002800050657

Cited by papers we hold 1

• Chemoresistance of glioblastoma cancer stem cells - much more complex than expected · 2011
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.